%PDF-1.4
%
27 0 obj
<>
endobj
24 0 obj
<>
endobj
86 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-12-02T19:08:12Z
2024-03-28T19:19:48-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-28T19:19:48-07:00
application/pdf
Heather
2001167.jan
uuid:341e5917-1dd2-11b2-0a00-4108277d8900
uuid:341e5919-1dd2-11b2-0a00-d30000000000
endstream
endobj
13 0 obj
<>
endobj
14 0 obj
<>
endobj
28 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
9 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
96 0 obj
[101 0 R]
endobj
97 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
/CS0 cs 0 0 0 0 scn
/GS1 gs
465 777 92 -27 re
f*
/CS0 CS 0 0 0 1 SCN
54 54 m
558 54 l
S
BT
0 0 0 1 scn
/TT0 1 Tf
0.02499 Tw 8 0 0 8 424.3613 35.9844 Tm
(The Journal of Rheumatology 2002; 29:1)Tj
0 Tw -46.2952 -0.0313 Td
(194)Tj
ET
0 0 0 0 scn
/GS0 gs
107.43 59.08 407.5 -10.83 re
f*
0.5 w
107.43 59.08 407.5 -10.83 re
S
BT
0 0 0 1 scn
/GS1 gs
/TT1 1 Tf
0.0432 Tw 9.7 0 0 10 54 713.1616 Tm
(This is especially important where leflunomide is used in the)Tj
0.0695 Tw 0 -1.2 TD
(treatment of conditions or diseases for which it has not been)Tj
0.01781 Tw T*
(specifically approved by drug regulatory agencies such as the)Tj
-0.00011 Tc 0.12 Tw T*
[(US Food and Drug )55 (Administration \(FDA\), and at doses not)]TJ
0.09869 Tw T*
[(currently used for the treatment of RA. RA)-294 (is at present the)]TJ
0 Tc -0.02499 Tw T*
[(only condition for which leflunomide is FDA)-170 (approved and its)]TJ
0.02499 Tw T*
[(ef)18 (ficacy has been adequately documented.)]TJ
0.0631 Tw 1.2371 -1.2 Td
[(Interestingly)65 (, despite the adverse reaction, our patient had)]TJ
0.2673 Tw -1.2371 -1.2 Td
(a clinically significant reduction in the clinical signs and)Tj
0.2494 Tw T*
(symptoms of the polychondritis while taking leflunomide.)Tj
0.03081 Tw T*
(Thus further evaluation of this agent for this condition would)Tj
0.02499 Tw T*
(appear to be appropriate.)Tj
/TT2 1 Tf
-0.00011 Tc 0 Tw 0 -2.4 TD
(REFERENCES)Tj
/TT1 1 Tf
0 Tc 0.02499 Tw 7.76 0 0 8 61.18 547.1616 Tm
[(1.)-387 (Product information: )55 (Arava)]TJ
0.0009 Tc 0 Tw 5.04 0 0 5.2 155.7197 549.8016 Tm
(TM)Tj
0 Tc 0.02499 Tw 7.76 0 0 8 163.2844 547.1616 Tm
[(, leflunomide. Kansas City: )55 (A)74 (ventis, Inc.;)]TJ
0 Tw -12.0212 -1.25 Td
(2000.)Tj
0.0249 Tw -1.1366 -1.25 Td
[(2.)-387 (Kraan M, Reece R, Bar)18 (g E. Modulation of inflammation and)]TJ
1.1366 -1.25 Td
(metalloproteinase expression in synovial tissue by leflunomide and)Tj
0 -1.25 TD
(methotrexate in patients with active rheumatoid arthritis: Findings in a\
)Tj
T*
(prospective, randomized, double-blind, parallel design clinical trial in\
)Tj
T*
[(39 patients at two centers. )55 (Arthritis Rheum 2000;43:1820-30.)]TJ
-1.1366 -1.25 Td
[(3.)-387 (Emery P)111 (, Breedveld FC, Lemmel EM. )55 (A)-220 (comparison of the ef)18 (ficacy)]TJ
1.1366 -1.25 Td
(and safety of leflunomide and methotrexate for the treatment of)Tj
T*
(rheumatoid arthritis. Rheumatology 2000;39:655-65.)Tj
-0.00011 Tc -1.1366 -1.25 Td
[(4.)-387 (Smolen JS, Kalden JR, Scott DL. Ef)18 (ficacy and safety of leflunomide)]TJ
0 Tc 1.1366 -1.25 Td
(compared with placebo and sulfasalazine in active rheumatoid arthritis:)Tj
T*
(a double-blind, randomized multi-center trial. European Leflunomide)Tj
T*
(Study Group. Lancet 1999;353:259-66.)Tj
32.884 37.171 Td
[(5.)-387 (Strand )18 (V)129 (, Cohen S, Schif)18 (f M. )18 (T)35 (reatment of active rheumatoid arthritis)]TJ
1.1366 -1.25 Td
[(with leflunomide compared with placebo and methotrexate. )55 (Arch)]TJ
T*
(Intern Med 1999;159:2542-50.)Tj
-1.1366 -1.25 Td
[(6.)-387 (Chong )55 (A, Huang )18 (W)92 (, Liu )18 (W)92 (. In vivo activity of leflunomide:)]TJ
1.1366 -1.25 Td
(Pharmacokinetic analyses and mechanism of immunosuppression.)Tj
T*
[(T)35 (ransplantation 1999;68:100-9.)]TJ
-1.1366 -1.25 Td
[(7.)-387 (Jaksch-W)80 (artenhorst R. Polychondropathia. )18 (W)40 (ien )55 (Arch Med 1923;)]TJ
0 Tw 1.1366 -1.25 Td
(6:93-100.)Tj
0.0249 Tw -1.1366 -1.25 Td
[(8.)-387 (Pearson CM, Kline HM, Newcomer )18 (VD. Relapsing polychondritis. )]TJ
1.1366 -1.25 Td
(N Engl J Med 1960;263:51-8.)Tj
-1.1366 -1.25 Td
[(9.)-387 (McAdam LP)111 (, O\222Hanlan MA, Bluestone R. Relapsing polychondritis:)]TJ
1.1366 -1.25 Td
(Prospective study of 23 patients and a review of the literature.)Tj
T*
(Medicine 1976;55:193-215.)Tj
-0.00011 Tc -1.6366 -1.25 Td
[(10.)-387 (T)35 (ishler M, Caspi D, )37 (Y)100 (aron M. Classical rheumatoid arthritis associated)]TJ
0 Tc 1.6366 -1.25 Td
(with nondeforming relapsing polychondritis. J Rheumatol)Tj
0 Tw T*
(1987;14:367-8.)Tj
-0.00011 Tc 0.02499 Tw -1.5997 -1.25 Td
[(1)37 (1.)-387 (Hager MH, Moore ME. Relapsing polychondritis syndrome associated)]TJ
0 Tc 1.5997 -1.25 Td
(with pustular psoriasis, spondylitis and arthritis mutilans. J Rheumatol\
)Tj
0 Tw T*
(1987;14:162-4.)Tj
0.02499 Tw -1.6366 -1.25 Td
[(12.)-387 (Michet CJ. )18 (V)111 (asculitis and relapsing polychondritis. Rheum Dis Clin)]TJ
-0.02991 Tw 1.6366 -1.25 Td
[(North Am )-55 (1990;16:441-4.)]TJ
0.0249 Tw -1.6366 -1.25 Td
[(13.)-387 (Y)111 (uh DD, Gandy KL, Morris RE, et al. Leflunomide prolongs)]TJ
1.6366 -1.25 Td
[(pulmonary allograft and xenograft survival. I. J Heart Lung )18 (T)35 (ransplant)]TJ
0 Tw T*
[(1995;14:1)37 (136-44.)]TJ
0.02499 Tw -1.6366 -1.25 Td
[(14.)-387 (Eckhardt SG, Rizzo J, Sweeney KR, et al. Phase I and pharmacologic)]TJ
1.6366 -1.25 Td
(study of the tyrosine kinase inhibitor SU101 in patients with advanced)Tj
T*
(solid tumors. J Clin Oncol 1999;17:1095-104.)Tj
ET
0 0 0 0 scn
468 770 90 -25 re
f*
Q
Q
q
0 0 612 792 re
W n
BT
0 g
ET
/GS2 gs
BT
/T1_0 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2002. All rights reserved.)Tj
ET
Q
BT
0 g
/GS3 gs
/T1_1 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS3 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS3 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
69 0 obj
<>
endobj
91 0 obj
<>
endobj
30 0 obj
<>
endobj
34 0 obj
<>
endobj
44 0 obj
<>
endobj
43 0 obj
<>
endobj
59 0 obj
<>stream
HdVpTs͋ ,1$^hG.4hyD*a@"d8#(Zjk;0[X0K"*hjE|Խ
{rs7 Cq7I?)5i,mX귫x.`nn竧?7/l?;w4w#[wl { 0cӞtYC'iL ٭m5([MړS`3Y-'
y{8wZHv1&Z0 >eX0oX؊Kȕ On"Բryhz4_`B+Bb2czb7*@b;b!Me뤀|7=Ya܊8.W۩磧f1~kiHGӽe7S6a2Y:O¤\ aw{~ơi=>$TJ{} EՂ{kl3x
b IjQJҶkӌ ޑ,ɖU:GUuE[q'^~QfKXZWucFkk2vVAN[||'2AdTK=iRZngd }VeY)Are:Ċ~'/1%Wӥr$U3ZY.H)ŤR=F sUfueT`GJSp:l-|/Vu-e{p|/qgя!3VȖq4UBRHe6@gDHnyDH~)9#^®UjSm Vnj,6C;GV5ժveDkݵF{YqoMasc#m =Z>I9z=%&?XؽHqw/5Nh
Z"n>V9mrIZ+Oɳa!cY~=Lf{9ߠRwV'8! [c440fhb`Zz:bNNN_X)vO.'3Z
/BL]ҁU]rNVW
9jGjcgq~+ƾǻUGxsR|Q}ͭ(7sS߹>t"/4/3
1EQ~ɰ܋/ʹC23,P];cb9ƞ5+v ASTyyj5Clf(:)9,Gmzu~?| Q_KHu*WtEcb3%,2B
;EkD<;uF(9skK`#3a=?Uwdk5{C)ZLj9*}\T쌰#Έ;N~pч:2UҬ.w4V:.{2&;%%~'-]Kb9Ex#C#Mdoմ /xMNV%OMzuwCE'a:ωXrt5SO0NXWcF}/$iE9_C&)%
v6ӿђ
Qmce i;DUHR\ԿzopOP#l("DyJVFL>`j;
߆^Y5p&5o@qVXQxV0uzpJ/f;fḶ(P^N2\67x16\˸<˭!vlgg̋kXdkXɵԼ};T?撬Ë=N8Oў\hڒJ:B<뼬akfd
FqكJZm>euڴ'p~&jf`\ZʙߌTLÛF-ITkсZi'>_R/L\E[z3ƘhK@j[L= qn5t,&WB`<~
5+iNfj=~sK-,z<{;asWf}߱ azѳݛm}'큕r>m}dZ{f/*;scrr
ʒ7PDo5 GTL0m㘎auN`!fLqFǴTkmTbmHcB;LMgwǭ@J. pPa]% *9T< N% 6XU`Q^ J *T`TIgD% X?Bp$ye|]"N//EKHEiA`zi_S\'1:k^WVFˡ4(TSSҬ`^B|!i~@n o gڄ}m£mBqPaſoi>,V"Dh/%L'pS4a<"^aMDȌ^[?|Wh^ԼSr7s9+9BSHpsYV)~D;"di#H8^#(!s%LM|DCOhHPPq+a[[7t7:~OW5E ]EL\Tt; 9pN "17%Q@}J4U)=JЩDasv `]6ԧŷ>-jǛ,nj_3\3zE4
8QZE^A+`p%NO(-W0ڙ(k